Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.

Autoantibodies Autoimmune cerebellar ataxia Autoimmune encephalitis Autoimmunity Cerebellitis Cerebellum Immunoglobulin G Immunoprecipitation Melanoma Paraneoplastic cerebellar degeneration Paraneoplastic neurological syndrome Septin-11 Septin-3 Septin-5 Septin-6 Septin-7 Septins Small-cell lung cancer

Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
30 Mar 2023
Historique:
received: 02 11 2022
accepted: 03 02 2023
medline: 3 4 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

Septins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodies against septin-7 with encephalopathy with prominent neuropsychiatric features. Here, we report on newly identified autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia. We also propose a strategy for anti-septin autoantibody determination. Sera from three patients producing similar immunofluorescence staining patterns on cerebellar and hippocampal sections were subjected to immunoprecipitation followed by mass spectrometry. The identified candidate antigens, all of which were septins, were expressed recombinantly in HEK293 cells either individually, as complexes, or combinations missing individual septins, for use in recombinant cell-based indirect immunofluorescence assays (RC-IIFA). Specificity for septin-3 was further confirmed by tissue IIFA neutralization experiments. Finally, tumor tissue sections were analyzed immunohistochemically for septin-3 expression. Immunoprecipitation with rat cerebellum lysate revealed septin-3, -5, -6, -7, and -11 as candidate target antigens. Sera of all three patients reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of 149 healthy control sera was similarly reactive. In RC-IIFAs the patient sera recognized only cells expressing septin-3, individually and in complexes. Incubation of patient sera with five different septin combinations, each missing one of the five septins, confirmed the autoantibodies' specificity for septin-3. The tissue IIFA reactivity of patient serum was abolished by pre-incubation with HEK293 cell lysates overexpressing the septin-3/5/6/7/11 complex or septin-3 alone, but not with HEK293 cell lysates overexpressing septin-5 as control. All three patients had cancers (2 × melanoma, 1 × small cell lung cancer), presented with progressive cerebellar syndromes, and responded poorly to immunotherapy. Expression of septin-3 was demonstrated in resected tumor tissue available from one patient. Septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Based on our findings, RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex may serve as a screening tool to investigate anti-septin autoantibodies in serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single septins.

Sections du résumé

BACKGROUND BACKGROUND
Septins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodies against septin-7 with encephalopathy with prominent neuropsychiatric features. Here, we report on newly identified autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia. We also propose a strategy for anti-septin autoantibody determination.
METHODS METHODS
Sera from three patients producing similar immunofluorescence staining patterns on cerebellar and hippocampal sections were subjected to immunoprecipitation followed by mass spectrometry. The identified candidate antigens, all of which were septins, were expressed recombinantly in HEK293 cells either individually, as complexes, or combinations missing individual septins, for use in recombinant cell-based indirect immunofluorescence assays (RC-IIFA). Specificity for septin-3 was further confirmed by tissue IIFA neutralization experiments. Finally, tumor tissue sections were analyzed immunohistochemically for septin-3 expression.
RESULTS RESULTS
Immunoprecipitation with rat cerebellum lysate revealed septin-3, -5, -6, -7, and -11 as candidate target antigens. Sera of all three patients reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of 149 healthy control sera was similarly reactive. In RC-IIFAs the patient sera recognized only cells expressing septin-3, individually and in complexes. Incubation of patient sera with five different septin combinations, each missing one of the five septins, confirmed the autoantibodies' specificity for septin-3. The tissue IIFA reactivity of patient serum was abolished by pre-incubation with HEK293 cell lysates overexpressing the septin-3/5/6/7/11 complex or septin-3 alone, but not with HEK293 cell lysates overexpressing septin-5 as control. All three patients had cancers (2 × melanoma, 1 × small cell lung cancer), presented with progressive cerebellar syndromes, and responded poorly to immunotherapy. Expression of septin-3 was demonstrated in resected tumor tissue available from one patient.
CONCLUSIONS CONCLUSIONS
Septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Based on our findings, RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex may serve as a screening tool to investigate anti-septin autoantibodies in serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single septins.

Identifiants

pubmed: 36997937
doi: 10.1186/s12974-023-02718-9
pii: 10.1186/s12974-023-02718-9
pmc: PMC10061979
doi:

Substances chimiques

Autoantibodies 0
septin 3 EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88

Informations de copyright

© 2023. The Author(s).

Références

Front Neurol. 2021 Apr 09;12:642800
pubmed: 33897597
N Engl J Med. 2000 Jan 6;342(1):21-7
pubmed: 10620645
J Clin Oncol. 2010 May 10;28(14):2460-6
pubmed: 20385998
J Neuroinflammation. 2010 Mar 12;7:21
pubmed: 20226058
Semin Cancer Biol. 2020 Aug;64:93-101
pubmed: 31330185
Ann Neurol. 2022 Dec;92(6):1090-1101
pubmed: 36053822
Int J Biol Macromol. 2019 Jul 15;133:428-435
pubmed: 31002902
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1359-62
pubmed: 16801349
Neurol Clin. 2018 Aug;36(3):675-685
pubmed: 30072076
J Neuroimmunol. 2013 Mar 15;256(1-2):94-6
pubmed: 23332614
Front Cell Dev Biol. 2021 Nov 19;9:765085
pubmed: 34869357
Neurology. 2021 Aug 10;97(6):291-292
pubmed: 34031206
Front Immunol. 2018 Jul 09;9:1447
pubmed: 30038610
Biol Chem. 2011 Aug;392(8-9):739-49
pubmed: 21767234
J Neuroinflammation. 2015 Sep 17;12:167
pubmed: 26377184
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Neuroinflammation. 2015 Sep 17;12:166
pubmed: 26377085
Ann Neurol. 2004 Oct;56(4):575-9
pubmed: 15389893
J Neurochem. 2004 Nov;91(3):579-90
pubmed: 15485489
Cerebellum. 2022 Aug;21(4):573-591
pubmed: 35020135
Br J Cancer. 2005 Sep 5;93(5):499-503
pubmed: 16136025
J Autoimmun. 2010 May;34(3):J322-6
pubmed: 20022216
Biochimie. 2012 Mar;94(3):628-36
pubmed: 21967827
J Neuroinflammation. 2015 Sep 17;12:168
pubmed: 26377319
J Neuroinflammation. 2022 Jul 30;19(1):196
pubmed: 35907972
Gene Expr. 2004;11(5-6):271-8
pubmed: 15200239
Ann Neurol. 2020 May;87(5):659-669
pubmed: 32086972
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 29;8(3):
pubmed: 33782191
Intern Med. 2008;47(8):747-9
pubmed: 18421192
J Neuroinflammation. 2014 Dec 11;11:206
pubmed: 25498830
Neurol Neuroimmunol Neuroinflamm. 2018 Jul 09;5(5):e474
pubmed: 29998156
Ther Adv Neurol Disord. 2021 Feb 1;14:1756286420985323
pubmed: 33796141
J Neurochem. 2007 Jul;102(1):77-92
pubmed: 17564677
Neurology. 2007 Jan 16;68(3):239-40
pubmed: 17224583
Neurology. 2020 Oct 27;95(17):e2442-e2452
pubmed: 32796130
Autoimmun Rev. 2020 Aug;19(8):102590
pubmed: 32561463
Lupus. 2010 May;19(6):753-5
pubmed: 20064909
Front Cell Dev Biol. 2016 Nov 09;4:122
pubmed: 27882315
Neurohospitalist. 2013 Apr;3(2):53-64
pubmed: 23983888
Clin Genet. 2010 Jun;77(6):511-24
pubmed: 20236126

Auteurs

Ramona Miske (R)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.

Madeleine Scharf (M)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany. m.scharf@euroimmun.de.

Kathrin Borowski (K)

Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.

Nicole Rieckhoff (N)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.

Bianca Teegen (B)

Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.

Yvonne Denno (Y)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.

Christian Probst (C)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.

Kersten Guthke (K)

Department of Neurology, Städtisches Klinikum Görlitz, Görlitz, Germany.

Ieva Didrihsone (I)

Department of Neurology, Hermann-Josef-Krankenhaus, Erkelenz, Germany.

Brigitte Wildemann (B)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Klemens Ruprecht (K)

Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Lars Komorowski (L)

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.

Sven Jarius (S)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH